Analysts’ Viewpoint on Gene Therapy Market Scenario
Although COVID-19 vaccines using viral vectors, nucleic acids, and proteins are helping to improve patient outcomes, there is a need for conducting continuous safety and efficiency evaluations over a long time period. However, the high cost of gene therapy products is emerging as a major restraint for the gene therapy market. Hence, companies should target selective marketing strategies toward high-income groups to increase its acceptance, which holds potentials to eventually reduce its cost in the upcoming decade. In this way, gene therapy companies can recover their costs for R&D investments. Different gene therapy approaches are being studied in the fields of oncology such as gene therapy-based immune modulation, anti-angiogenic gene therapy, oncolytic virotherapy, and the likes.
Gene therapy is being publicized as an important treatment alternative, as it helps to eliminate the usage of surgery, drugs, or other procedures, which can have side effects. Mergers and acquisitions (M&A) in the gene therapy market is helping stakeholders to boost R&D in neurological gene therapy products in order to treat infants with spinal muscular atrophy (SMA) type 1 (SMA1).
Companies in the gene therapy market are striving to acquire the U.S. FDA’s (Food and Drug Administration) approval for CAR-T cell therapy products for use in the treatment of appropriate R/R (relapsed or refractory) patients with large B-cell lymphoma. New gene therapy candidates hold potentials to receive the rare pediatric disease designation as well as approval for use in the treatment of metachromatic leukodystrophy from the FDA.
Companies in the gene therapy market are under scrutiny for developing COVID-19 vaccines using different technologies that are classified into four groups (nucleic acids, intact target viruses, proteins and viral vectors). New wave of Coronavirus in Shanghai, China is compelling biotechnology companies and research institutes to continuously run their R&D activities for the introduction of better treatment options.
High chances of moderate and severe symptoms with pneumonia due to the novel coronavirus is compelling academic institutes to increase research for the development of RNA vaccines and adenovirus vector vaccines that have been urgently approved.
Despite several advantages, gene therapy is a highly expensive treatment alternative, which is depriving people from underdeveloped countries of Africa and developing economies of India to opt for it, thus impeding growth of the gene therapy market. High cost of gene therapy and limited reimbursement packages tend to deter patients from availing the treatment. Such findings are restraining gene therapy companies from meeting their expected revenue targets.
It has been found that gene therapy products for the treatment of retinal dystrophy is priced approximately US$ 8,50,000 per treatment, making it the world’s most expensive gene therapy. Since gene therapy products undergo high R&D investment, companies in the gene therapy market should selectively target patients from high income groups to increase its acceptance. They should conduct surveys and develop focus groups to gain insights about individual preferences for gene therapy products.
An uptick in success rates with gene therapy and new gene therapy product approvals have led to an increased demand for more number of treatment centers in the U.S. and Europe. After initial success rates of gene therapy, companies in the gene therapy market strive to increase the number of treatment centers in order to gain access to a large patient pool requiring gene therapy treatments.
The gene therapy product which has been approved for the treatment of patients up to the age of 25 years affected with large B-cell lymphoma, has only 41 treatment centers in the U.S., which limits a large number of patients from receiving gene therapy treatment. Hence, investment in treatment centers is necessary to increase clinical numbers.
Commercialization of gene therapy products in different areas of unmet medical needs to gain the first mover advantage and increasing competition among the leading biopharmaceutical companies to approve the products is expected to boost growth in the gene therapy market during the forecast period.
Next-gen gene therapy products are receiving marketing approval for the treatment of patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency, due to Adenosine Deaminase deficiency). Strimvelis is the first ex-vivo stem cell gene therapy to be approved in Europe for the treatment of ADA-SCID.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 1.3 Bn |
|
Market Forecast Value in 2028 |
US$ 5.3 Bn |
|
Growth Rate (CAGR) |
19.8% |
|
Forecast Period |
2021–2028 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Gene Therapy Market – Segmentation
| Product |
|
| End-user |
|
| Region |
|
Gene therapy market is expected to reach the value of US$ 5.3 Bn by the end of 2028
Gene therapy market is estimated to expand at a CAGR of 19.8% from 2021 to 2028
Gene therapy market is driven by high prevalence and increase in incidence rate of different types of cancers
Europe accounted for a major share of the global gene therapy market
Key players in the global gene therapy market includes Novartis AG, Orchard Therapeutics Limited, Celgene Corporation, Spark Therapeutics, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gene Therapy Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Region/globally
5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Gene Therapy Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2018–2030
6.3.1. Yescarta
6.3.2. Kymriah
6.3.3. Luxturna
6.3.4. Strimvelis
6.3.5. Gendicine
6.3.6. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Gene Therapy Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2018–2030
7.3.1. Ophthalmology
7.3.2. Oncology
7.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
7.4. Market Attractiveness Analysis, by Application
8. Global Gene Therapy Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Global Gene Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2018–2030
9.2.1. Yescarta
9.2.2. Kymriah
9.2.3. Luxturna
9.2.4. Strimvelis
9.2.5. Gendicine
9.2.6. Others
9.3. Market Value Forecast, by Application, 2018–2030
9.3.1. Ophthalmology
9.3.2. Oncology
9.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
9.4. Market Value Forecast, by Country, 2018–2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country
10. Europe Global Gene Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2018–2030
10.2.1. Yescarta
10.2.2. Kymriah
10.2.3. Luxturna
10.2.4. Strimvelis
10.2.5. Gendicine
10.2.6. Others
10.3. Market Value Forecast, by Application, 2018–2030
10.3.1. Ophthalmology
10.3.2. Oncology
10.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
10.4. Market Value Forecast, by Country, 2018–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country
11. Asia Pacific Global Gene Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2018–2030
11.2.1. Yescarta
11.2.2. Kymriah
11.2.3. Luxturna
11.2.4. Strimvelis
11.2.5. Gendicine
11.2.6. Others
11.3. Market Value Forecast, by Application, 2018–2030
11.3.1. Ophthalmology
11.3.2. Oncology
11.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
11.4. Market Value Forecast, by Country, 2018–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country
12. Latin America Global Gene Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2018–2030
12.2.1. Yescarta
12.2.2. Kymriah
12.2.3. Luxturna
12.2.4. Strimvelis
12.2.5. Gendicine
12.2.6. Others
12.3. Market Value Forecast, by Application, 2018–2030
12.3.1. Ophthalmology
12.3.2. Oncology
12.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
12.4. Market Value Forecast, by Country, 2018–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country
13. Middle East & Africa Global Gene Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2018–2030
13.2.1. Yescarta
13.2.2. Kymriah
13.2.3. Luxturna
13.2.4. Strimvelis
13.2.5. Gendicine
13.2.6. Others
13.3. Market Value Forecast, by Application, 2018–2030
13.3.1. Ophthalmology
13.3.2. Oncology
13.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
13.4. Market Value Forecast, by Country, 2018–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Application
13.5.3. By Country
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Company Profiles
14.2.1. Novartis AG
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.1.2. Financial Overview
14.2.1.3. Product Portfolio
14.2.1.4. SWOT Analysis
14.2.1.5. Strategic Overview
14.2.2. Orchard Therapeutics Limited
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.2.2. Financial Overview
14.2.2.3. Product Portfolio
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Celgene Corporation
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.3.2. Financial Overview
14.2.3.3. Product Portfolio
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Spark Therapeutics, Inc.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.4.2. Financial Overview
14.2.4.3. Product Portfolio
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Gilead Sciences, Inc.
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.5.2. Financial Overview
14.2.5.3. Product Portfolio
14.2.5.4. SWOT Analysis
14.2.5.5. Strategic Overview
14.2.6. Sibiono GeneTech Co. Ltd.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.6.2. Financial Overview
14.2.6.3. Product Portfolio
14.2.6.4. SWOT Analysis
14.2.6.5. Strategic Overview
14.2.7. Other prominent players
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.7.2. Financial Overview
14.2.7.3. Product Portfolio
14.2.7.4. SWOT Analysis
14.2.7.5. Strategic Overview
List of Table
Table 01: Global Gene Therapy Market Value (US$ Mn) Forecast, by Product, 2017‒2028
Table 02: Global Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028
Table 03: Global Gene Therapy Market Value (US$ Mn) Forecast, by Region, 2017‒2028
Table 04: North America Gene Therapy Market Value (US$ Mn) Forecast, by Product,2017‒2028
Table 05: North America Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028
Table 06: North America Gene Therapy Market Value (US$ Mn) Forecast, by Country, 2017‒2028
Table 07: Europe Gene Therapy Market Value (US$ Mn) Forecast, by Product,2017‒2028
Table 08: Europe Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028
Table 09: Europe Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028
Table 10: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, by Product,2017‒2028
Table 11: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028
Table 12: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028
Table 13: Latin America Gene Therapy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 14: Latin America Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028
Table 15: Latin America Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028
Table 16: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 17: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, by Applications, 2017‒2028
Table 18: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2028
List of Figure
Figure 01: Global Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028
Figure 02: Gene Therapy Market Value Share, by Product, 2020
Figure 03: Gene Therapy Market Value Share, by Applications – Use, 2020
Figure 04: Global Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028
Figure 05: Global Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028
Figure 06: Global Gene Therapy Market Value (US$ Mn), by Yescarta, 2017–2028
Figure 07: Global Gene Therapy Market Value (US$ Mn), by Kymriah, 2017–2028
Figure 08: Global Gene Therapy Market Value (US$ Mn), by Luxturna, 2017–2028
Figure 09: Global Gene Therapy Market Value (US$ Mn), by Strimvelis, 2017–2028
Figure 10: Global Gene Therapy Market Value (US$ Mn), by Gendicine, 2017–2028
Figure 11: Global Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028
Figure 12: Global Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028
Figure 13: Global Gene Therapy Market Value (US$ Mn), by Ophthalmology, 2017–2028
Figure 14: Global Gene Therapy Market Value (US$ Mn), by Oncology, 2017–2028
Figure 15: Global Gene Therapy Market Value (US$ Mn), by Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID), 2017–2028
Figure 16: Global Gene Therapy Market Value Share Analysis, by Region, 2020 and 2028
Figure 17: Global Gene Therapy Market Attractiveness Analysis, by Region, 2017–2028
Figure 18: North America Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028
Figure 19: North America Gene Therapy Market Value Share Analysis, Product, 2020 and 2028
Figure 20: North America Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028
Figure 21: North America Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028
Figure 22: North America Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028
Figure 23: North America Gene Therapy Market Value Share Analysis, by Country, 2020 and 2028
Figure 24: North America Gene Therapy Market Attractiveness Analysis, by Country, 2017–2028
Figure 25: Europe Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028
Figure 26: Europe Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028
Figure 27: Europe Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028
Figure 28: Europe Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028
Figure 29: Europe Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028
Figure 30: Europe Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028
Figure 31: Europe Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028
Figure 32: Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028
Figure 33: Asia Pacific Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028
Figure 34: Asia Pacific Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028
Figure 35: Asia Pacific Gene Therapy Market Value Share Analysis, by Applications , 2020 and 2028
Figure 36: Asia Pacific Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028
Figure 37: Asia Pacific Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028
Figure 38: Asia Pacific Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028
Figure 39: Latin America Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028
Figure 40: Latin America Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028
Figure 41: Latin America Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028
Figure 42: Latin America Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028
Figure 43: Latin America Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028
Figure 43: Latin America Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028
Figure 44: Latin America Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028
Figure 45: Middle East & Africa Gene Therapy Market Value (US$ Mn) Forecast, 2017–2028
Figure 46: Middle East & Africa Gene Therapy Market Value Share Analysis, by Product, 2020 and 2028
Figure 47: Middle East & Africa Gene Therapy Market Attractiveness Analysis, by Product, 2017–2028
Figure 48: Middle East & Africa Gene Therapy Market Value Share Analysis, by Applications, 2020 and 2028
Figure 49: Middle East & Africa Gene Therapy Market Attractiveness Analysis, by Applications, 2017–2028
Figure 50: Middle East & Africa Gene Therapy Market Value Share Analysis, by Country/Sub-Region, 2020 and 2028
Figure 51: Middle East & Africa Gene Therapy Market Attractiveness Analysis, by Country/Sub-Region, 2017–2028
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gene Therapy Market
